| Literature DB >> 35932398 |
Takashi Oyama1, Kosei Kageyama2, Hideki Araoka3, Takashi Mitsuki4, Kyosuke Yamaguchi1, Daisuke Kaji1, Yuki Taya1, Aya Nishida4, Kazuya Ishiwata4, Shinsuke Takagi1, Hisashi Yamamoto1, Go Yamamoto1, Yuki Asano-Mori1, Naoyuki Uchida1, Atsushi Wake4, Shigeyoshi Makino5, Shuichi Taniguchi1.
Abstract
Bacterial meningitis is a rare but severe infectious complication after hematopoietic stem cell transplantation. However, its clinical features were previously not clear. We reviewed the cases of 7 patients diagnosed with bacterial meningitis with a positive cerebrospinal fluid culture among 1147 patients who underwent cord blood transplantation (CBT) at our institution between September 2007 and September 2020. The diagnosis was made on day + 5- + 45, and 5 patients developed bacterial meningitis before neutrophil engraftment. The causative organisms were all Gram-positive cocci: Enterococcus faecium and Enterococcus gallinarum (2 patients each), and Staphylococcus haemolyticus, Streptococcus mitis/oralis, and Rothia mucilaginosa (1 patient each). Six patients developed bacterial meningitis secondary to prior or concomitant bacteremia caused by the same bacterium. Five patients had received anti-MRSA agents at onset: vancomycin in 3, teicoplanin in 1, and daptomycin in 1. After diagnosis of bacterial meningitis, linezolid was eventually used for 6 patients. Two patients with E. gallinarum were alive at day + 1380 and + 157 after CBT, respectively, whereas 5 patients died 17-53 (median 43) days after the onset of bacterial meningitis. Breakthrough meningitis in CBT can occur even during the use of anti-MRSA drugs, and intensive antibiotic treatment is necessary.Entities:
Keywords: Anti-MRSA drugs; Bacterial meningitis; Breakthrough infection; Cord blood transplantation
Year: 2022 PMID: 35932398 DOI: 10.1007/s12185-022-03425-6
Source DB: PubMed Journal: Int J Hematol ISSN: 0925-5710 Impact factor: 2.319